Join the Cisplatin group to help and get support from people like you.
Cisplatin News
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 – For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly...
Platinum Chemo Shortage Led to Reduced Use, No Change in Mortality
MONDAY, Dec. 30, 2024 – The platinum chemotherapy shortage, first announced on Feb. 10, 2023, resulted in a modest absolute reduction in platinum use, but no difference in mortality, according to a...
Last Year's Platinum-Based Drugs Shortage Didn't Raise Cancer Deaths, Study Found
TUESDAY, Dec. 24, 2024 – When supplies of certain generic, platinum-based cancer chemotherapies dwindled in 2023, oncologists feared it might lead to under-treatment and many more cancer deaths....
There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take Cisplatin
TUESDAY, Nov. 26, 2024 – Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit the drug. A new trial...
2023 Cisplatin Shortage Tied to Use of Alternatives for Head, Neck Cancer
TUESDAY, Oct. 1, 2024 – The 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
RAHWAY, N.J.--(BUSINESS WIRE) November 1, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
Further information
Related condition support groups
Non-Small Cell Lung Cancer, Ovarian Cancer